206 related articles for article (PubMed ID: 8816835)
21. Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity.
Matsui M; Kishida T; Nakano H; Yoshimoto K; Shin-Ya M; Shimada T; Nakai S; Imanishi J; Yoshimoto T; Hisa Y; Mazda O
Cancer Res; 2009 Mar; 69(6):2523-30. PubMed ID: 19244121
[TBL] [Abstract][Full Text] [Related]
22. In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells.
Hefeneider SH; Conlon PJ; Henney CS; Gillis S
J Immunol; 1983 Jan; 130(1):222-7. PubMed ID: 6600178
[TBL] [Abstract][Full Text] [Related]
23. [Effect of lymphokine-activated killer cells of head and neck tumors in vitro and in nude mice].
Duan DS
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993; 28(5):281-3, 314. PubMed ID: 8192930
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
[TBL] [Abstract][Full Text] [Related]
25. [Combined interleukin-2 and herpes simplex virus thymidine kinase gene therapy for head and neck squamous cell carcinoma].
Liu S; Liang C; Yang H; Xian J
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2001 Dec; 36(6):426-9. PubMed ID: 12761956
[TBL] [Abstract][Full Text] [Related]
26. Neem leaf glycoprotein induces perforin-mediated tumor cell killing by T and NK cells through differential regulation of IFNgamma signaling.
Bose A; Chakraborty K; Sarkar K; Goswami S; Chakraborty T; Pal S; Baral R
J Immunother; 2009 Jan; 32(1):42-53. PubMed ID: 19307993
[TBL] [Abstract][Full Text] [Related]
27. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.
Andrews KJ; Ribas A; Butterfield LH; Vollmer CM; Eilber FC; Dissette VB; Nelson SD; Shintaku P; Mekhoubad S; Nakayama T; Taniguchi M; Glaspy JA; McBride WH; Economou JS
Cancer Res; 2000 Nov; 60(22):6457-64. PubMed ID: 11103813
[TBL] [Abstract][Full Text] [Related]
28. [Adoptive immunotherapy by intra-arterial infusion of ATLAK or Allo-TLAK cells in patients with head and neck cancer].
Ikawa T; Eura M; Fukiage T; Murakami H; Yamasaki S; Fukuda K; Fukushima M; Arishima S; Maehara T; Ishikawa T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1438-47. PubMed ID: 2786378
[TBL] [Abstract][Full Text] [Related]
29. Antitumor and antiangiogenic effects of interleukin 12 gene therapy in murine head and neck carcinoma model.
Imagawa Y; Satake K; Kato Y; Tahara H; Tsukuda M
Auris Nasus Larynx; 2004 Sep; 31(3):239-45. PubMed ID: 15364358
[TBL] [Abstract][Full Text] [Related]
30. Characterization and tumorigenicity of human neuroblastoma cells transfected with the IL-2 gene.
Corrias MV; Basso S; Meazza R; Musiani P; Santi L; Bocca P; Occhino M; Ferrini S; Pistoia V
Cancer Gene Ther; 1998; 5(1):38-44. PubMed ID: 9476965
[TBL] [Abstract][Full Text] [Related]
31. Cytotoxicity tests against cultured human lung cancer cells with autologous lymphocytes activated in vitro by mitomycin C-treated tumor monolayers in the presence of T-cell growth factor.
Kimura H; Yamaguchi Y; Kadoyama C; Sato N; Fujisawa T
Jpn J Clin Oncol; 1983 Mar; 13(1):3-13. PubMed ID: 6300483
[TBL] [Abstract][Full Text] [Related]
32. A murine model for the immunotherapy of head and neck squamous cell carcinoma.
Hier MP; Black MJ; Shenouda G; Sadeghi N; Karp SE
Laryngoscope; 1995 Oct; 105(10):1077-80. PubMed ID: 7564839
[TBL] [Abstract][Full Text] [Related]
33. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma.
Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Kurimoto M
Cancer Res; 1997 Oct; 57(20):4557-63. PubMed ID: 9377569
[TBL] [Abstract][Full Text] [Related]
34. Granulocyte-macrophage colony-stimulating factor in a combination gene therapy strategy for head and neck cancer.
Day KV; Li D; Liu S; Guo M; O'Malley BW
Laryngoscope; 2001 May; 111(5):801-6. PubMed ID: 11368071
[TBL] [Abstract][Full Text] [Related]
35. Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model.
Hess SD; Egilmez NK; Shiroko J; Bankert RB
Cancer Gene Ther; 2001 May; 8(5):371-7. PubMed ID: 11477457
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
37. IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones.
Tsutsui H; Nakanishi K; Matsui K; Higashino K; Okamura H; Miyazawa Y; Kaneda K
J Immunol; 1996 Nov; 157(9):3967-73. PubMed ID: 8892629
[TBL] [Abstract][Full Text] [Related]
38. Leukocyte Interleukin, Inj. (LI) augmentation of natural killer cells and cytolytic T-lymphocytes.
Chirigos MA; Talor E; Sidwell RW; Burger RA; Warren RP
Immunopharmacol Immunotoxicol; 1995 May; 17(2):247-64. PubMed ID: 7650289
[TBL] [Abstract][Full Text] [Related]
39. [Antitumor activity of adherent LAK cells (A-LAK) in a model of squamous carcinoma of the head and neck].
Sacchi M; Galeazzi E; Johnson JT; Cavalot AL; Cortesina G
Acta Otorhinolaryngol Ital; 1991; 11(4):405-15. PubMed ID: 1792895
[TBL] [Abstract][Full Text] [Related]
40. [Combination radiation and gene therapy for head and neck squamous cell carcinoma in the murine model].
Liu SX; Yang H; Yuan YM; Guo YF; Tang ZQ; Liang CY
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2004 May; 39(5):278-82. PubMed ID: 15338865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]